Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature
- 27 April 2024
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 42 (7) , 737-749
Abstract
Cost-effectiveness analyses commonly use population or sample averages, which can mask key differences across subgroups and may lead to suboptimal resource allocation. Despite there being several new methods developed over the last decade, there is no recent summary of what methods are available to researchers. This review sought to identify advances in methods for addressing patient heterogeneity in economic evaluations and to provide an overview of these methods. A literature search was conducted using the Econlit, Embase and MEDLINE databases to identify studies published after 2011 (date of a previous review on this topic). Eligible studies needed to have an explicit methodological focus, related to how patient heterogeneity can be accounted for within a full economic evaluation. Sixteen studies were included in the review. Methodologies were varied and included regression techniques, model design and value of information analysis. Recent publications have applied methodologies more commonly used in other fields, such as machine learning and causal forests. Commonly noted challenges associated with considering patient heterogeneity included data availability (e.g., sample size), statistical issues (e.g., risk of false positives) and practical factors (e.g., computation time). A range of methods are available to address patient heterogeneity in economic evaluation, with relevant methods differing according to research question, scope of the economic evaluation and data availability. Researchers need to be aware of the challenges associated with addressing patient heterogeneity (e.g., data availability) to ensure findings are meaningful and robust. Future research is needed to assess whether and how methods are being applied in practice.Keywords
This publication has 72 references indexed in Scilit:
- Using causal forests to assess heterogeneity in cost‐effectiveness analysisHealth Economics, 2021
- The High Cost of Prescription Drugs in the United StatesJAMA, 2016
- ESTIMATING PERSON‐CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTSJournal of Applied Econometrics, 2013
- Use of instrumental variables in the presence of heterogeneity and self‐selection: an application to treatments of breast cancer patientsHealth Economics, 2007
- A taxonomy of model structures for economic evaluation of health technologiesHealth Economics, 2006
- Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluationsHealth Economics, 2005
- Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness dataHealth Economics, 2003
- Stratified cost‐effectiveness analysis: a framework for establishing efficient limited use criteriaHealth Economics, 2003
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002
- Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysisHealth Economics, 2001